Stock Events

Stock Events

Enlivex 

$0.79
22
-$0.05-6.34% Today

Statistics

Day High
0.85
Day Low
0.78
52W High
2.1
52W Low
0.66
Volume
625,183
Avg. Volume
576,473
Mkt Cap
19.07M
P/E Ratio
0.04
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.16
-0.13
-0.11
-0.08
Expected EPS
-0.0823
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-30.03MNet Income

Analyst Ratings

20Average Price Target
The highest estimate is 20.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENLV. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap1.96B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions.
Fate Therapeutics
FATE
Mkt Cap144.17M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex.
Novartis
NVS
Mkt Cap297.35B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases.
Allogene Therapeutics
ALLO
Mkt Cap663.08M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the innovative treatment space alongside Enlivex.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.

About

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Show more...
CEO
Mr. Shai Novik M.B.A.
Employees
71
Country
Israel
ISIN
IL0011319527

Listings

STU
DE
1BT.STU
F
DE
1BT.F
TA
IL
ENLV.TA
XNAS
US
ENLV

0 Comments

Share your thoughts

FAQ

What is Enlivex stock price today?▼
The current price of ENLV is $0.79 USD — it has decreased by -6.34% in the past 24 hours. Watch Enlivex stock price performance more closely on the chart.
What is Enlivex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enlivex stocks are traded under the ticker ENLV.
Is Enlivex stock price growing?▼
ENLV stock has fallen by -4.02% compared to the previous week, the month change is a -23.09% fall, over the last year Enlivex has showed a -9.74% decrease.
What is Enlivex market cap?▼
Today Enlivex has the market capitalization of 19.07M
When is the next Enlivex earnings date?▼
Enlivex is going to release the next earnings report on May 22, 2026.
What were Enlivex earnings last quarter?▼
ENLV earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.09 USD resulting in a -65.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enlivex revenue for the last year?▼
Enlivex revenue for the last year amounts to 0 USD.
What is Enlivex net income for the last year?▼
ENLV net income for the last year is -30.03M USD.
How many employees does Enlivex have?▼
As of April 14, 2026, the company has 71 employees.
In which sector is Enlivex located?▼
Enlivex operates in the Technology sector.
When did Enlivex complete a stock split?▼
The last stock split for Enlivex was on March 06, 2019 with a ratio of 1:8.
Where is Enlivex headquartered?▼
Enlivex is headquartered in Ness Ziona, Israel.